[Form 4] ARROWHEAD PHARMACEUTICALS, INC. Insider Trading Activity

Arrowhead Pharmaceuticals director reports stock grant.

Rhea-AI Filing Summary

Arrowhead Pharmaceuticals director reports stock grant. A director of Arrowhead Pharmaceuticals, Inc. reported receiving 7,819 shares of common stock on 12/16/2025 at a price of $0. These shares represent restricted stock units that will vest in a single installment on the first anniversary of the grant date, as long as the director continues to serve the company through that date.

After this grant, the director beneficially owns 64,930 shares of Arrowhead common stock in direct ownership. The filing indicates it was made by a single reporting person serving as a director of the company.

Insider Trade Summary

Grant/Award: 7,819 shares

Grant/Award 1 txn

Insider Waddill William D.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	7,819	$0.00	$0.00

Holdings After Transaction: Common Stock — 64,930 shares (Direct)

Footnotes (1)

1. F1. Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Arrowhead Pharmaceuticals (ARWR) report in this filing?

A director of Arrowhead Pharmaceuticals, Inc. reported receiving 7,819 shares of common stock as a restricted stock unit grant on 12/16/2025 at a price of $0.

How many Arrowhead Pharmaceuticals (ARWR) shares does the insider own after this transaction?

Following the reported grant, the director beneficially owns 64,930 shares of Arrowhead Pharmaceuticals common stock in direct ownership.

What are the vesting terms of the 7,819 restricted stock units at Arrowhead Pharmaceuticals (ARWR)?

The 7,819 restricted stock units will vest in one installment on the first anniversary of the grant date, subject to the director’s continued service to Arrowhead Pharmaceuticals on that date.

What is the role of the reporting person at Arrowhead Pharmaceuticals (ARWR)?

The reporting person is a director of Arrowhead Pharmaceuticals, as indicated in the relationship section of the filing.

Was the Arrowhead Pharmaceuticals (ARWR) insider transaction made under a Rule 10b5-1 trading plan?

The form includes a checkbox for transactions made under a Rule 10b5-1(c) trading plan, but the excerpt does not indicate that this specific box was checked for the reported grant.

What type of security did the Arrowhead Pharmaceuticals (ARWR) director acquire?

The director acquired common stock of Arrowhead Pharmaceuticals through a grant of restricted stock units that settle into shares upon vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 12/18/2025 - 06:35 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Waddill William D.

(Last) (First) (Middle)

177 E. COLORADO BLVD

SUITE 700

(Street)

PASADENA CA 91105

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARROWHEAD PHARMACEUTICALS, INC. [ ARWR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/16/2025		A		7,819(1)	A	$0	64,930	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares underlying restricted stock units, which shares will vest in one installment on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such date.

Remarks:

	/s/William Waddill	12/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.